0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.

      Arteriosclerosis, Thrombosis, and Vascular Biology
      Apolipoprotein A-I, biosynthesis, metabolism, Apolipoprotein A-II, blood, Arteriosclerosis, drug therapy, Cholesterol, HDL, Dose-Response Relationship, Drug, Double-Blind Method, Gemfibrozil, pharmacology, Hepatocytes, Humans, Hypolipidemic Agents, Lipids, Lipoproteins, HDL, chemistry, Niacin, Tumor Cells, Cultured

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Evidence indicates that the high density lipoprotein (HDL) subfraction containing apolipoprotein A-I without apolipoprotein AII (LP-AI) is more antiatherogenic than HDL particles containing apolipoprotein A-I and apolipoprotein A-II (LP-AI+AII). This study examined the effect of extended-release niacin (niacin-ER) and gemfibrozil on LP-AI and LP-AI+AII particles in patients with low levels of HDL cholesterol (HDL-C). Mechanisms by which these agents modulate HDL particles were investigated by in vitro studies using human hepatoblastoma (Hep G2) cells. A total of 139 patients with low HDL-C (

          Related collections

          Author and article information

          Comments

          Comment on this article